EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY 4.0

Single-dose ION775, a GalNAc-conjugated siRNA targeting APOC3, lowers triglycerides for up to 12 months in moderate hypertriglyceridemia

Sotirios Tsimikas, Erin Morgan, Jyoti Sharma, Tao Lin, Adam E Mullick, Thazha P Prakash, Eric E Swayze, Thomas A Prohaska

Journal of Clinical Lipidology · 2026

DOI: 10.1016/j.jacl.2026.08.012 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Lipidology, 2026. Verfasst von Sotirios Tsimikas und 7 weiteren Autor:innen. Beteiligte Einrichtung: Ionis Pharmaceuticals, Carlsbad, CA, USA (Tsimikas, Morgan, Sharma, Lin, Mullick, Prakash, Swayze, Prohaska); Division of Cardiovascular Medicine, Un…. Hauptthemen laut MEDLINE: Apolipoprotein C-III, Hypertriglyceridemia, Triglycerides, RNA, Small Interfering. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ionis Pharmaceuticals Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Apolipoprotein C-III (apoC-III) regulates triglyceride-rich lipoprotein metabolism. ION775 is a GalNAc-conjugated small interfering RNA designed to silence APOC3 mRNA and enable infrequent dosing. OBJECTIVE: To evaluate the safety, tolerability, and lipid effects of single-dose ION775 in adults with moderate hypertriglyceridemia. METHODS: In this phase 1 randomized, double-blind, placebo-controlled, single-ascending-dose study, adults with fasting triglycerides of 150 to 500 mg/dL received a single subcutaneous dose of ION775 (10-600 mg) or placebo and were followed for up to 12 months. The primary endpoint was safety and tolerability; pharmacodynamic endpoints included changes in apoC-III, triglycerides, and related lipid parameters. RESULTS: Forty participants were treated (ION775, n = 30; placebo, n = 10). ION775 was generally well tolerated, with no serious adverse events, severe treatment-emergent adverse events, or injection-site reactions. At 6 months, mean apoC-III changes ranged from -35.3% to -86.8% across active doses (all P ≤ 0.0047 vs placebo), and triglyceride changes ranged from -26.2% to -68.4%, with significant reductions at doses ≥30 mg (P ≤ 0.0017). Across the 30- to 600-mg groups, calculated remnant cholesterol, non-high-density lipoprotein cholesterol, and apoB were reduced by 61.4% to 72.7%, 21.8% to 33.9%, and 20.0% to 29.1%, respectively (P ≤ 0.0075, P = 0.0002, and P ≤ 0.0047 vs placebo, respectively). In the 300- and 600-mg cohorts, apoC-III and triglyceride reductions were sustained through 12 months. CONCLUSION: Single-dose ION775 was generally well tolerated and produced rapid, dose-dependent, durable reductions in apoC-III and triglycerides sustained through 12 months, supporting further development as an infrequently dosed therapy for triglyceride-rich lipoprotein disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Apolipoprotein C-IIIHypertriglyceridemiaTriglyceridesRNA, Small InterferingAcetylgalactosamineHumansFemaleMaleAdultMiddle AgedDouble-Blind Method

Stichwörter der Autor:innen

APOC3ApoBApolipoprotein C-IIIHypertriglyceridemiaION775Remnant cholesterolSiRNATriglycerides

Substanzen

Apolipoprotein C-IIITriglyceridesRNA, Small InterferingAcetylgalactosamine

Autor:innen und Institutionen

  • Ionis Pharmaceuticals, Carlsbad, CA, USA (Tsimikas, Morgan, Sharma, Lin, Mullick, Prakash, Swayze, Prohaska); Division of Cardiovascular Medicine, University of California San Diego, La Jolla, CA, USA (Tsimikas). Electr…
  • Ionis Pharmaceuticals, Carlsbad, CA, USA (Tsimikas, Morgan, Sharma, Lin, Mullick, Prakash, Swayze, Prohaska).

Förderung

  • Ionis Pharmaceuticals Inc

Zitieren

APA

Tsimikas, S., Morgan, E., Sharma, J., Lin, T., Mullick, A. E., Prakash, T. P., Swayze, E. E., & Prohaska, T. A. (2026). Single-dose ION775, a GalNAc-conjugated siRNA targeting APOC3, lowers triglycerides for up to 12 months in moderate hypertriglyceridemia. Journal of Clinical Lipidology. https://doi.org/10.1016/j.jacl.2026.08.012

Vancouver

Tsimikas S, Morgan E, Sharma J, Lin T, Mullick AE, Prakash TP, et al. Single-dose ION775, a GalNAc-conjugated siRNA targeting APOC3, lowers triglycerides for up to 12 months in moderate hypertriglyceridemia. Journal of Clinical Lipidology. 2026. doi:10.1016/j.jacl.2026.08.012

BibTeX
@article{Tsimikas2026,
  author = {Tsimikas, Sotirios and Morgan, Erin and Sharma, Jyoti and Lin, Tao and Mullick, Adam E and Prakash, Thazha P and Swayze, Eric E and Prohaska, Thomas A},
  title = {Single-dose ION775, a GalNAc-conjugated siRNA targeting APOC3, lowers triglycerides for up to 12 months in moderate hypertriglyceridemia},
  journal = {Journal of Clinical Lipidology},
  year = {2026},
  doi = {10.1016/j.jacl.2026.08.012}
}
Kostenlos starten →